| PCCM | pediatric critical care medicine; primary care case management; primary care case manager |
|---|---|
| PCP | parachlorophenate; patient care plan; pentachlorophenol; 1-(1-phenylcyclohexyl)piperidine; periphera... |
| PCS | palliative care service; Patient Care System; patterns of care study; pelvic congestion syndrome; ph... |
| PCU | pain control unit; primary care unit; patient care unit; pulmonary care unit |
| RC | an electronic circuit containing a resistor and capacitor in series; radiocarpal; reaction center; r... |
| total iron binding capacity | <biochemistry, haematology> A test that measures indirectly the transferrin level in the bloodstream. Transferrin is a protein that carries iron in the body. Normal values are 240 to 450 mcg/dl. This test is used to evaluate anaemia. Greater than normal total iron binding capacity can be seen in: iron deficiency anaemia, late pregnancy and polycythaemia vera. Lower than normal total iron binding capacity can be seen in cirrhosis, sickle cell anaemia, hypoproteinaemia, pernicious anaemia and haemolytic anaemia. The use of birth control pills can lead to increased total iron binding capacity measurements. Acronym: TIBC (12 Jan 1998) |
|---|---|
| ferric citrate iron reductase | <enzyme> Requires fmn, uses NADH; fre1 and fre2 provide membrane-associated ferric reductase activity for saccharomyces cerevisiae Registry number: EC 1.6.99.- Synonym: ferric iron reductase, iron reductase, ferric reductase, NADH-dependent, ferrireductase, iron (iii) reductase, ferric reductase, fre1 gene product, fre2 gene product, ferric-chelate reductase, NADH-dependent ferric-chelate reductase, NADH-dependent iron(iii)-chelate reductase, fecitr, NADH-fe(iii)-chelate reductase, nfr enzyme (26 Jun 1999) |
| Lillie's ferrous iron stain | <technique> A method using potassium ferrocyanide in acetic acid which demonstrates melanins as a deep green colour; lipofuscins and haem pigments are unreactive. (05 Mar 2000) |
| administration, oral | The giving of drugs, chemicals, or other substances by mouth. (12 Dec 1998) |
| cancer, oral | Cancer of the mouth area. A sore in the mouth that does not heal can be a warning sign of oral cancer. A biopsy is the only to know whether as abnormal area in the oral cavity is cancer. Oral cancer is caused by tobacco (smoking and chewing) and alcohol use. Surgery to remove the tumour in the mouth is the usual treatment for patients with oral cancer. (12 Dec 1998) |
| candidiasis, oral | Infection of the mucous membranes of the mouth by a fungus of the genus candida. (12 Dec 1998) |
| canine oral papilloma | Warts affecting mucous membranes of young dogs; caused by a papillomavirus. (05 Mar 2000) |
| magnesia and alumina oral suspension | A mixture of magnesium hydroxide and variable amounts of aluminum oxide; used as an antacid. (05 Mar 2000) |
| pathology, oral | A dental specialty concerned with pathology of the oral cavity. (12 Dec 1998) |
| pharyngo-oral | Relating to the pharynx and the mouth; oropharyngeal. Origin: pharyngo-+ L. Os (or-), mouth (05 Mar 2000) |
| combination oral contraceptive | A mixture of a steroid having progestational activity and an oestrogen. (05 Mar 2000) |
| contraceptives, oral | Compounds, usually hormonal, taken orally in order to block ovulation and prevent the occurrence of pregnancy. The hormones are generally oestrogen or progesterone or both. (12 Dec 1998) |
| contraceptives, oral, combined | Fixed drug combinations administered orally for contraceptive purposes. (12 Dec 1998) |
| contraceptives, oral, hormonal | Oral contraceptives which owe their effectiveness to hormonal preparations. (12 Dec 1998) |
| contraceptives, oral, sequential | Drugs administered orally and sequentially for contraceptive purposes. (12 Dec 1998) |